Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients

Nalesnik, MA and Locker, J and Jaffe, R and Reyes, J and Cooper, M and Fung, J and Starzl, TE (1992) Experience with posttransplant lymphoproliferative disorders in solid organ transplant recipients. Clinical Transplantation, 6 (3 II). 249 - 252. ISSN 0902-0063

Accepted Version
Available under License : See the attached license file.

Download (638kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Nearly 6000 solid organ transplants have been performed at the University of Pittsburgh since 1981. Posttransplant lymphoproliferative disorders (PTLD) have occurred in 131 patients, at a frequency of 2.2%. The majority of cases manifest within 6 months following allograft, but individual lesions may arise several years thereafter. From 1981 to 1989, cyclosporine-A (CsA) served as the primary immunosuppressant in this population. In March of 1989, FK506 was introduced for clinical trials. Since that time, 1421 patients have received FK506 either for primary immunosuppression or as rescue therapy. The frequency of PTLD in this subpopulation is 1.5%. PTLD arising under FK506-containing regimens have clinicopathologic features similar to those arising with CsA immunosuppression. The frequency of PTLD at this point in time is approximately 1%, in kidney allograft patients, 2.7% in liver, 3.3% in heart and 3.8%, in heart/lung or lung recipients. An understanding of the range of histologic appearance is important for the diagnosis of PTLD, especially when it involves the allograft itself. Immunoglobulin heavy chain gene analysis shows that lesions with no rearrangements or with a rearrangement in only a small proportion of cells are more likely to respond to reduced immunosuppression than are those with clonal rearrangement involving a high proportion of cells. However, this distinction is not absolute, and a trial of reduced immunosuppression appears to be indicated regardless of clonal status.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Nalesnik, MAnalesnik@pitt.eduNALESNIK
Locker, J
Jaffe, R
Reyes, J
Cooper, M
Fung, J
Starzl, TEtes11@pitt.eduTES11
Centers: Other Centers, Institutes, Offices, or Units > Thomas E. Starzl Transplantation Institute
Date: 14 July 1992
Date Type: Publication
Journal or Publication Title: Clinical Transplantation
Volume: 6
Number: 3 II
Page Range: 249 - 252
Event Type: Conference
Institution: University of Pittsburgh
Refereed: Yes
ISSN: 0902-0063
Other ID: uls-drl:31735062111731, Starzl CV No. 1385
Date Deposited: 08 Apr 2010 17:23
Last Modified: 04 Feb 2019 15:57


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item